Conversely, a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study clearly showed that not only baseline proteinuria, but also changes in proteinuria in the first 6 months of therapy were related to the degree of long-term renal protection in proteinuric patients with T2D [69]. Here, AGT is linked to type 2 diabetes mellitus.